Phibro Animal Health (PAHC) Competitors $21.98 +0.08 (+0.37%) Closing price 04:00 PM EasternExtended Trading$21.98 0.00 (-0.02%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PAHC vs. AKRO, PTCT, CRNX, RYTM, ACLX, DNLI, IMVT, TWST, XENE, and ACADShould you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Akero Therapeutics (AKRO), PTC Therapeutics (PTCT), Crinetics Pharmaceuticals (CRNX), Rhythm Pharmaceuticals (RYTM), Arcellx (ACLX), Denali Therapeutics (DNLI), Immunovant (IMVT), Twist Bioscience (TWST), Xenon Pharmaceuticals (XENE), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Phibro Animal Health vs. Akero Therapeutics PTC Therapeutics Crinetics Pharmaceuticals Rhythm Pharmaceuticals Arcellx Denali Therapeutics Immunovant Twist Bioscience Xenon Pharmaceuticals ACADIA Pharmaceuticals Akero Therapeutics (NASDAQ:AKRO) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer AKRO or PAHC? In the previous week, Akero Therapeutics had 49 more articles in the media than Phibro Animal Health. MarketBeat recorded 56 mentions for Akero Therapeutics and 7 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.85 beat Akero Therapeutics' score of 0.56 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 15 Very Positive mention(s) 6 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AKRO or PAHC more profitable? Phibro Animal Health has a net margin of 1.67% compared to Akero Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 21.59% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Phibro Animal Health 1.67%21.59%5.85% Which has better earnings & valuation, AKRO or PAHC? Phibro Animal Health has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$3.75-14.76Phibro Animal Health$1.02B0.87$2.42M$0.4351.12 Do analysts rate AKRO or PAHC? Akero Therapeutics presently has a consensus target price of $66.29, indicating a potential upside of 19.74%. Phibro Animal Health has a consensus target price of $20.50, indicating a potential downside of 6.73%. Given Akero Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Akero Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Phibro Animal Health 2 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the MarketBeat Community believe in AKRO or PAHC? Phibro Animal Health received 200 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 64.77% of users gave Akero Therapeutics an outperform vote while only 60.15% of users gave Phibro Animal Health an outperform vote. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes11464.77% Underperform Votes6235.23% Phibro Animal HealthOutperform Votes31460.15% Underperform Votes20839.85% Do institutionals and insiders believe in AKRO or PAHC? 99.3% of Phibro Animal Health shares are held by institutional investors. 7.9% of Akero Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, AKRO or PAHC? Akero Therapeutics has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. SummaryPhibro Animal Health beats Akero Therapeutics on 12 of the 17 factors compared between the two stocks. Get Phibro Animal Health News Delivered to You Automatically Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PAHC vs. The Competition Export to ExcelMetricPhibro Animal HealthPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$890.19M$6.93B$5.62B$9.14BDividend Yield2.21%2.95%5.36%3.98%P/E Ratio51.1210.1189.6917.66Price / Sales0.87351.361,220.3881.09Price / Cash10.2965.4844.3437.71Price / Book3.475.335.134.73Net Income$2.42M$157.56M$118.85M$225.42M7 Day Performance0.50%2.83%1.87%-0.44%1 Month Performance4.82%2.84%7.96%3.57%1 Year Performance95.03%8.37%26.70%19.20% Phibro Animal Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PAHCPhibro Animal Health4.0907 of 5 stars$21.98+0.4%$20.50-6.7%+87.8%$890.19M$1.02B51.121,940Upcoming EarningsAnalyst UpgradeNews CoverageAKROAkero Therapeutics4.1492 of 5 stars$51.37+96.2%$50.50-1.7%+129.1%$3.59BN/A-13.7030Analyst ForecastInsider TradeAnalyst RevisionNews CoverageGap UpHigh Trading VolumePTCTPTC Therapeutics3.8881 of 5 stars$46.07-0.8%$55.00+19.4%+60.6%$3.55B$937.82M-7.761,410CRNXCrinetics Pharmaceuticals3.787 of 5 stars$38.21-1.5%$72.64+90.1%+4.5%$3.54B$4.01M-10.24210Short Interest ↑RYTMRhythm Pharmaceuticals3.7949 of 5 stars$56.42-2.4%$68.09+20.7%+27.2%$3.47B$77.43M-13.03140ACLXArcellx2.9852 of 5 stars$62.93-0.1%$105.93+68.3%+0.3%$3.40B$155.82M-88.6380Short Interest ↑DNLIDenali Therapeutics4.499 of 5 stars$23.19+4.4%$38.91+67.8%+33.6%$3.34B$330.53M-8.40430Analyst ForecastShort Interest ↑IMVTImmunovant1.751 of 5 stars$22.40-2.8%$47.00+109.8%-44.6%$3.29BN/A-10.09120TWSTTwist Bioscience2.5907 of 5 stars$52.23-3.4%$51.90-0.6%+42.4%$3.10B$312.97M-14.51990Upcoming EarningsInsider TradeNews CoverageXENEXenon Pharmaceuticals2.6644 of 5 stars$40.11+0.4%$56.00+39.6%-13.6%$3.06B$9.43M-14.22210Insider TradeAnalyst RevisionPositive NewsACADACADIA Pharmaceuticals4.0074 of 5 stars$18.27-2.1%$25.25+38.2%-33.3%$3.04B$726.44M23.42510Short Interest ↑Analyst Revision Related Companies and Tools Related Companies AKRO Competitors PTCT Competitors CRNX Competitors RYTM Competitors ACLX Competitors DNLI Competitors IMVT Competitors TWST Competitors XENE Competitors ACAD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PAHC) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phibro Animal Health Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phibro Animal Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
